Nephrol Dial Transplant (2003) 18: III42-III46
© 2003 European Renal Association-European Dialysis and Transplant Association
Original Article
Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients
1 Center of Blood Purification Therapy and 2 The First Department of Pathology, Wakayama Medical University, Wakayama, Japan
Background. The impetus to develop percutaneous calcitriol injection therapy (PCIT) was the lack of therapeutic tools to treat secondary hyperparathyroidism (2HPT) resistant to medical therapy.
Methods. Nine dialysis patients resistant to intravenous calcitriol or calcitriol analogues underwent daily PCIT 510 times consecutively. The PCIT involved the injection of a volume of calcitriol equal to that of the enlarged parathyroid glands (PTGs) under ultrasonographic guidance. All patients had follow-up intravenous calcitriol after PCIT.
Results. The serum intact PTH concentration was markedly reduced following PCIT and was maintained for 12 weeks with intravenous calcitriol without significant changes in serum adjusted calcium and phosphorus concentrations. All patients tolerated PCIT without serious adverse events. Serum bone alkaline phosphatase concentrations and the volume of the enlarged PTGs were also significantly reduced.
Conclusion. PCIT is a safe and effective treatment, which may also suppress parathyroid hyperplasia and improve bone turnover for refractory 2HPT.
Keywords: calcitriol; end-stage renal disease (ESRD); interventional ultrasonography; renal osteodystrophy; secondary hyperparathyroidism
Correspondence and offprint requests to: Kazuhiro Shiizaki, Center of Blood Purification Therapy, Wakayama Medical University, 811-1 Kimiidera Wakayama 641-0012, Japan. Email: shiizaki{at}wakayama-med.ac.jp
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K. Shiizaki, I. Hatamura, S. Negi, E. Nakazawa, R. Tozawa, S. Izawa, T. Akizawa, and E. Kusano Cellular changes following direct vitamin D injection into the uraemia-induced hyperplastic parathyroid gland NDT Plus, August 1, 2008; 1(suppl_3): iii42 - iii48. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Shiizaki, I. Hatamura, S. Negi, T. Sakaguchi, F. Saji, I. Imazeki, E. Kusano, T. Shigematsu, and T. Akizawa Highly Concentrated Calcitriol and its Analogues Induce Apoptosis of Parathyroid Cells and Regression of the Hyperplastic Gland Study in Rats Nephrol. Dial. Transplant., December 21, 2007; (2007) gfm850v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Drueke, D. Martin, and M. Rodriguez Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1828 - 1839. [Full Text] [PDF] |
||||
![]() |
K. Shiizaki, N. Hayakawa, I. Imazeki, I. Hatamura, T. Okada, S. Negi, T. Sakaguchi, T. Shigematsu, and T. Akizawa Binding of highly concentrated maxacalcitol to the nuclear vitamin D receptors of parathyroid cells Nephrol. Dial. Transplant., April 1, 2007; 22(4): 1078 - 1086. [Abstract] [Full Text] [PDF] |
||||

